scispace - formally typeset
S

Stanley Nattel

Researcher at Montreal Heart Institute

Publications -  802
Citations -  72437

Stanley Nattel is an academic researcher from Montreal Heart Institute. The author has contributed to research in topics: Atrial fibrillation & Heart failure. The author has an hindex of 132, co-authored 778 publications receiving 65700 citations. Previous affiliations of Stanley Nattel include Mayo Clinic & Brigham and Women's Hospital.

Papers
More filters
Journal ArticleDOI

Electrophysiological effects of alpha-adrenergic stimulation.

TL;DR: Conduction and refractoriness of normal cardiac tissue (other than the sinus node) are unaffected by direct α‐receptor stimulation, which justifies the use of combined beta and muscarinic blockers to achieve autonomic blockade under most circumstances.
Journal Article

Prognostic implications of transient left ventricular cavitary dilation during exercise and dipyridamole-thallium imaging.

TL;DR: Patients with dipyridamole-inducedTLVD are at greater risk than those with exercise-induced TLVD at the authors' institution, and both fatal and nonfatal cardiac events were more frequent in the dipyrinole group.
Journal ArticleDOI

Close connections between contraction and rhythm: a new genetic cause of atrial fibrillation/cardiomyopathy and what it can teach us

TL;DR: This editorial refers to ‘A frameshift deletion in the sarcomere gene MYL4 causes early-onset familial atrial fibrillation’, by D.F. Gudbjartsson et al.
Journal ArticleDOI

Nuclear factor of activated T cells mediates RhoA-induced fibronectin upregulation in glomerular podocytes

TL;DR: The results indicate that RhoA activates NFAT by inducing a rise of [Ca(2+)]i in podocytes, which in turn contributes to fibronectin upregulation, which may be responsible for the pathogenesis of certain glomerular diseases such as hypertension-mediated glomerulosclerosis.
Journal ArticleDOI

Cardiac pathways distinguish two epistatic modules enacting BP quantitative trait loci and candidate gene analysis

TL;DR: The lack of an amino-acid alteration, coupled with a lack of difference in the α1-Na-K-ATPase activity, excluded ATPase, Na+/K+-transporting, α-1 polypeptide as a candidate gene for C2QTL6, a novel diagnostic and/or therapeutic target for essential hypertension and hypertension-associated diseases.